Standard BioTools (LAB)

The company is best known for platforms built around mass cytometry and microfluidics. Its CyTOF technology enables single-cell proteomics by allowing researchers to measure many protein markers across individual cells, while its Hyperion imaging systems extend proteomic analysis into tissue samples for spatial biology applications. Standard BioTools also offers genomics systems such as the Biomark X9, which is used for high-throughput genetic analysis and other molecular workflows.

These technologies are used by pharmaceutical companies, biotechnology developers, academic institutions and research laboratories that need reproducible biological data across complex samples. The company’s revenue base includes hardware sales as well as recurring demand for reagents, assays, chips, panels, software and support services connected to its installed instruments.

Standard BioTools operates internationally across the Americas, Europe, the Middle East, Africa and Asia-Pacific. Its market position is tied to long-term growth in precision medicine, immune profiling, oncology research and other areas where researchers require deeper measurement of cells, proteins and genes. As a listed life sciences tools company, Standard BioTools offers investors exposure to the research infrastructure behind biomedical innovation rather than to a single drug candidate.